National Cancer Institute-Molecular Analysis for Therapy Choice, known as NCI-MATCH or study EAY131, is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.
Patient Eligibility Overview
The trial is for cancer patients who meet all of the following pre-qualifications:
The trial is available at about 1,100 cancer centers and community hospitals in every state, the District of Columbia, and Puerto Rico. For locations, visit the NCI website.
Following are the commercial laboratories that have been designated to identify patients for the NCI-MATCH trial as part of their normal genomic tumor testing procedures:
Patients at the following designated cancer center labs may be tested for tumor gene abnormalities using the institutional assay:
The new process does not apply to patients tested by a designated laboratory prior to May 11, 2017.
Designated labs will look for tumor gene abnormalities being studied in NCI-MATCH as part of their normal testing procedures. When a treating physician at a site that is participating in the trial orders genomic sequencing (tumor gene testing) from the designated lab to guide clinical care for his or her patient, the lab will look for trial matches in the patient. If found, the lab will include the information in the broader genomic testing report to the ordering physician, as just one potential treatment option. The oncologist can take the information into consideration when discussing treatment options with his or her patient.
Tumor testing by a designated lab is the only pathway for new patients to enroll into the trial, effective May 11, 2017.
The trial’s expert panel will review the case of every patient who receives a treatment assignment.
Cancer patients who consent to enrolling in the NCI-MATCH trial will do so knowing in advance that they have a tumor gene abnormality matching one being studied in the trial and that they meet certain disease inclusion and exclusion requirements. Once enrolled for screening (Step 0) a patient’s treating oncologist will need to evaluate them further for the specific eligibility requirements for the treatment arm to which they match.
Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.
Once enrolled, patients will be treated with a drug or drug combination that targets the molecular changes in their tumor for as long as their tumor shrinks or remains stable.
Collectively, the designated labs conduct sequencing for tens of thousands of people with cancer, which is necessary to identify patients whose tumor gene abnormalities match those being studied in the trial. To help the trial adjust to the high volumes of patient cases, there is a demonstration project in place whereby the labs will initially only report on 19 treatment arms. These 19 arms address rare gene abnormalities that rarely occur (in 1.5 percent or fewer of patients tested thus far in the trial).
The demonstration project also stages laboratory involvement. Foundation Medicine, Inc. and The University of Texas MD Anderson Cancer Center reporting to physicians went into effect on May 11, 2017. Caris Life Sciences® began reporting to physicians on June 23, 2017. Memorial Sloan Kettering Cancer Center will begin reporting to physicians in late June or early July 2017.
The potential inclusion of other treatment arms in the trial will be considered once the demonstration project is complete (late summer or early fall 2017).
Treatment Arms in NCI-MATCH
For a full listing of all treatment arms in NCI-MATCH and their status, visit the Active Trials Table.
Laboratory Vetting Criteria
Trial leaders designated these laboratories because of their capabilities in three areas:
ECOG-ACRIN Website Resources
Contacts at Designated Laboratories
For more information about genomic sequencing, send an email to the designated laboratory:
NCI-MATCH (EAY131) Study Contact
Inquiries about the NCI-MATCH (EAY131) study may be directed to:
ECOG-ACRIN Cancer Research Group
Operations Office – Boston
|Trial Educational Materials|
|NCI-MATCH / EAY131 for Researchers|
|ECOG Performance Status|